Zepbound and Mounjaro contain the same active ingredient, tirzepatide, made by the same company, Eli Lilly. There is no chemical difference between them at a given dose. They cost different amounts anyway, and understanding why is the difference between overpaying by $600 a year and not.
The reason is regulatory, not pharmaceutical. Lilly holds two separate FDA applications for tirzepatide and markets them under two brand names for two different approved uses. Each brand has its own self-pay price, its own savings card with its own caps, its own list price, and its own Medicare treatment. This guide prices both ladders as published on September 4, 2026 and shows exactly where the gap sits. For single-brand detail see our Zepbound cost guide and our Mounjaro cost guide.
What Does Zepbound vs. Mounjaro Cost Without Insurance?
Every figure below was read directly from Lilly’s own pages and CMS data on September 4, 2026.
| Route | Low | Average | High |
|---|---|---|---|
| Zepbound self-pay, LillyDirect (KwikPen or 4 vials) | $299/mo (2.5 mg) | $449/mo (7.5 to 15 mg) | $699/mo (10 to 15 mg, regular price) |
| Mounjaro self-pay, LillyDirect (single-dose pen) | $499/mo | $499/mo | $499/mo |
| Savings card, commercial plan covers the drug | $25/mo | $25/mo | Savings capped, see below |
| Savings card, commercial plan excludes the drug | $299/mo (Zepbound 2.5 mg) | $449/mo (Zepbound maintenance) | $499/mo (Mounjaro, any dose) |
| Medicare GLP-1 Bridge, if eligible | $50/mo (Zepbound KwikPen only) | not available for Mounjaro | not available for Zepbound vials or pens |
| What the pharmacy pays (CMS NADAC, Aug 19 2026) | $482/mo (Zepbound KwikPen) | $678/mo (Zepbound KwikPen 12.5 mg) | $1,077/mo (Mounjaro pen) |
| Manufacturer list price (WAC, accessed Jan 1 2026) | $499 per Zepbound fill | $1,086.37 per Zepbound fill | $1,112.16 per Mounjaro fill |
Zepbound’s self-pay ladder on LillyDirect reads $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg. The $449 is conditional: Lilly’s footnote states those prices reflect the Zepbound Journey Program, and regular prices apply if the prescription is not refilled within 45 days, at $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg. Lilly’s pricing page states the unconditioned direct-to-patient ladder as $299, $399, $499, $699, $699 and $699.
Mounjaro’s LillyDirect page carries one price, repeated on all six dose cards: $499 a month on the single-dose prefilled pen, where a month is 28 days and four pens. There is no dose ladder and no refill-timing condition.
One format caveat that matters when you compare the two. Lilly’s savings page states that the $299 per month price is for the Zepbound KwikPen or vial, not the Zepbound single-dose Pen. Mounjaro’s self-pay price applies to the single-dose pen. So the cheapest Zepbound and the only Mounjaro are not the same device, which is worth knowing before you assume the products are interchangeable at the counter. Our Zepbound KwikPen and Zepbound vials guides cover the format split.
The gap, per month and per year
At the top of the titration schedule, a cash payer on Zepbound at $449 spends $5,388 across 12 months. The same person on Mounjaro at $499 spends $5,988. The gap is $50 a month and $600 a year.
At the 2.5 mg starting dose the gap is much wider, $200 a month, because Zepbound starts at $299 while Mounjaro does not discount the starting dose at all. At 5 mg it is $100 a month.
The gap can also reverse. If you are at 10 mg or higher on Zepbound and miss the 45-day refill window, your price becomes $699 and Mounjaro at $499 is suddenly the cheaper product by $200 a month, or $2,400 a year. That is the single most expensive avoidable mistake on either program.
What Drives the Price
The indication on the prescription. This is the whole story. Lilly markets Zepbound for weight management and Mounjaro to improve blood sugar in people with type 2 diabetes aged 10 and up, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them. Lilly’s card terms on both brands require a prescription for an approved use consistent with FDA-approved labeling. Your diagnosis routes you to a brand, and the brand sets the price.
Device format, which is not cosmetic. CMS’s National Average Drug Acquisition Cost survey, effective August 19, 2026, prices the Zepbound KwikPen at roughly $482 to $678 for a 28-day month, the Zepbound single-dose pen at about $1,051, and the Mounjaro single-dose pen at about $1,077. Same molecule, same doses, and the multi-dose KwikPen costs pharmacies less than half what the single-dose pens cost. That is the structural reason Lilly can price the KwikPen route at $299 to $449.
List price, which differs by brand. Lilly publishes a Zepbound list price of $499 to $1,086.37 per fill and a Mounjaro list price of $1,112.16 per fill, both wholesale acquisition cost figures drawn from AnalySource on January 1, 2026. If you ever pay something close to list, that $26 to $613 per-fill difference is real money.
Refill timing, on Zepbound only. Mounjaro’s $499 has no calendar condition attached. Zepbound’s $449 does.
No generic competition on either side. Both brands are the same patented molecule from one manufacturer, so nothing outside Lilly’s own programs pushes these prices down. Our tirzepatide cost guide covers the patent and compounding picture at the molecule level.
Cash Price vs. Insurance
The two savings cards look similar and are not. Both require commercial drug insurance and both exclude government beneficiaries and the uninsured, and both expire 12/31/2026.
On the Mounjaro card, a commercially insured patient whose plan covers Mounjaro may pay as little as $25 for a one-month, two-month or three-month fill, with savings capped at $150 per one-month fill and $1,950 per calendar year across up to 13 fills. If the plan does not cover Mounjaro, the card price is $499 for a one-month fill, capped at $647 in savings per month and $8,411 a year.
On the Zepbound card, the $25 tier applies to the single-dose Pen for patients whose commercial plan covers it, with savings capped at $100 per one-month fill and $1,300 a year across up to 13 fills. Patients with commercial insurance that does not cover Zepbound get the KwikPen at $299, $399 or $449 by dose, with stated maximum monthly savings of $215, $115, $65 and $271 depending on strength.
Read that carefully, because it is the most useful comparison on this page: an uninsured person pays $449 for maintenance-dose Zepbound and $499 for Mounjaro, which is exactly what a commercially insured person without coverage pays. On these two drugs, having insurance that excludes them buys you nothing over having no insurance at all.
Medicare splits the two brands hardest. Medicare.gov states that from July 1, 2026 the temporary Medicare GLP-1 Bridge covers the Zepbound KwikPen at a $50 monthly copay, does not cover single-dose Zepbound vials or pens, and does not list Mounjaro at all. It also states you are not eligible if you have type 2 diabetes, on the reasoning that your Part D plan may cover a GLP-1 for that condition. Self-pay purchases do not count toward any deductible or out-of-pocket maximum.
How to Pay Less
-
Buy manufacturer-direct on whichever brand you are prescribed. LillyDirect is the floor for both. CMS acquisition data shows the pharmacy itself pays more than $1,000 a month for the single-dose pen presentations, so a walk-in counter is not going to undercut $449 or $499.
-
Ask your prescriber what you qualify for rather than which is cheaper. The brands are approved for different conditions. Asking what your diagnosis supports is a fair question. Asking to switch brands purely on price is not something either you or your prescriber can act on.
-
Guard the Zepbound 45-day refill window if you are on Zepbound. At 10 mg and above it is the difference between $449 and $699. Our cheapest way to get Zepbound guide and our Zepbound savings card page cover the eligibility rules in detail.
-
Check the card even if your plan excludes the drug. Both brands have a second card tier for commercially insured patients without coverage. It will not beat self-pay, but it costs nothing to confirm which tier you are in.
-
Budget the prescribing visit and follow-up separately. These are ongoing prescriptions. A free or sliding-scale clinic can cover the visits at low cost, and if a lab or clinic bill from the workup goes sideways, our guide to negotiating medical bills covers what to say. Our fair price checker shows typical cash rates for the visit itself.
-
Recheck before every refill. Lilly has restructured these self-pay tiers more than once since 2024, both savings cards expire 12/31/2026, and the Medicare GLP-1 Bridge runs only through December 31, 2027.
Bottom Line
In September 2026 a cash payer pays $299 to $449 a month for Zepbound and a flat $499 for Mounjaro, which is $5,388 versus $5,988 across a year at a maintenance dose. The molecule is identical. The price is not, because the FDA application, the brand, the device and the program are all different.
You cannot shop across that gap. What you can control is buying direct rather than at a counter, keeping the Zepbound refill clock if you are on Zepbound, and knowing that the Medicare Bridge reaches only the Zepbound KwikPen. If you are comparing across molecules rather than brands, see our Zepbound vs. Wegovy cost comparison and the class-wide GLP-1 cost guide.